Synact Pharma Ab Is A Clinical Stage Biotechnology Company Based In Lundswedenfounded In 2012The Company Specializes In Developing Therapies That Promote Inflammation Resolution Through Melanocortin Biologytargeting Autoimmune And Inflammatory Diseasesthe Leadership Team Includes Ceo Jeppe Ovlesen And Other Key Executiveswith A Small Team Of Six Employees The Company S Primary Technology Involves Selectively Activating Melanocortin Receptors To Induce Anti Inflammatory Effectssynact S Pipeline Features Resomelagonap1189 Which Is In Phase 2 Trials For Rheumatoid Arthritisidiopathic Membranous Nephropathyand Covid 19 Related Respiratory Complicationsadditionallytxp 11 Is In Preclinical Development As A Peptide Agonist Aimed At Preventing Organ Failure During Surgerysynact Plans To License Its Clinical Assets After Achieving Phase Ii Proof Of Conceptfocusing On Collaborations With Larger Pharmaceutical Companies For Further Development
